• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Don’t Be Outfoxed By Dems' Win

Don’t Be Outfoxed By Dems' Win

November 14, 2006
CenterWatch Staff

The Democrats’ decisive victory in Tuesday’s mid-term election put them in control of the House, but it is widely seen as bad news for the pharmaceutical industry. Dire predictions of drug price controls have many in big pharma concerned. Pharma should be worried—especially if it sticks to the old game plan.

But the Democrats’ moves against the drug industry are not likely to be as drastic as warnings suggest. So long out of power, the Democrats don’t want to revert to their old ways and to be seen as the anti-business party. They have a chance to take the middle road where they can be perceived as both pro-business and pro-consumer...

Democrats will want to recast their old image of anti-business regulators ahead of the presidential election in two years. The reasonable center is usually the best course in presidential politics.

And a number of newly elected Democratic Congressmen are more conservative than Nancy Pelosi, anticipated to be House Speaker. They may help bring the party to the center. A party in the middle doesn’t usually go to extremes.

And even if Democrats take narrow control of the Senate, it will still be a divided government that is less likely to take punitive action against a particular industry. Democrats will have their hands full, launching Congressional hearings about the war in Iraq or taking on other out-of-favor industries such as Big Oil. While Big Pharma has been vilified in the mainstream press, Big Oil’s huge profits are an easier target. Pharma also has the advantage over Big Oil because it is an industry that provides hope with life-saving treatments.

Certainly, Pharma will be on the Democrats’ hit list, but the industry has a chance to make some compromises that would stop short of dreaded price controls. Of course, the Democrats will want some symbolic victory on drug prices to take to the voters in 2008.

If Pharma doesn’t find a way to work well with Congress this year, and if a Democrat wins the White House in two years, then all bets are off.

Pharma, ironically, may want to turn to a big stem cell research supporter such as actor Michael J. Fox, who successfully helped a Missouri Democrat win Tuesday night with his backing of the issue. The Parkinson disease sufferer and his foundation know well how difficult and expensive research for a new drug treatment is. Wiping out drug company profits doesn’t help research efforts. While industry has to back off its high estimates of how much it costs to develop a new drug, it remains a very expensive and risky enterprise.

Democratic supporters of stem cell research can be pharma industry allies—as long as all sides take the middle road and don’t get too greedy.

Upcoming Events

  • 26Jan

    Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup

  • 27Jan

    Medical Device Clinical Trials in China: Latest Regulatory Developments

  • 11Feb

    Lab X.0: Addressing Quality and Compliance Challenges in Laboratory Operations in the COVID-19 All-Digital Era

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 26Apr

    MAGI's Clinical Research vConference — Spring 2021

Featured Products

  • Regenerative Medicine – Steps to Accelerate Development : PDF

    Regenerative Medicine: Steps to Accelerate Development

  • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

    Clinical Trial Agreements: A Guide to Key Words and Phrases

Featured Stories

  • Virtual Doctoer

    Simple Changes Can Make Trials More Patient Friendly

  • Drug approval

    Two-Thirds of Trial Subjects for Drug Approvals Are Outside the U.S.

  • VaccinewithNeedle-360x240.png

    Rules of Vaccine Approval May Be Changing, But Statistical Analysis Tools Remain Constant

  • AskTheExperts-360x240.png

    Ask the Experts: Trial Operations Adjustments in a Remote World

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing